NeuroPace, Inc. (NASDAQ:NPCE) Stock Has Average Price Target of $19.33 According to Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has been given an average recommendation of “Moderate Buy” by the ten analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $19.33.

NPCE has been the subject of a number of research reports. Raymond James Financial set a $21.00 target price on shares of NeuroPace in a report on Tuesday, September 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a research report on Monday. Mizuho began coverage on NeuroPace in a report on Thursday, July 23rd. They set an “outperform” rating and a $22.00 target price for the company. KeyCorp started coverage on NeuroPace in a research report on Thursday, September 17th. They issued an “overweight” rating and a $18.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of NeuroPace in a research note on Wednesday, July 29th.

Institutional Investors Weigh In On NeuroPace

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in NeuroPace during the 2nd quarter valued at about $39,369,000. First Light Asset Management LLC increased its holdings in shares of NeuroPace by 82.3% in the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after purchasing an additional 1,110,484 shares during the period. Deutsche Bank AG purchased a new stake in shares of NeuroPace in the second quarter worth approximately $14,919,000. GSA Capital Partners LLP purchased a new stake in shares of NeuroPace in the second quarter worth approximately $1,836,000. Finally, Man Group plc acquired a new stake in shares of NeuroPace during the second quarter worth approximately $1,336,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Price Performance

NASDAQ:NPCE opened at $14.06 on Wednesday. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. The business’s 50-day moving average price is $14.44 and its 200 day moving average price is $15.25. NeuroPace has a 52-week low of $9.22 and a 52-week high of $19.60. The firm has a market cap of $482.54 million, a P/E ratio of -24.67 and a beta of 1.94.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. The company had revenue of $22.83 million during the quarter, compared to the consensus estimate of $22.61 million. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. As a group, sell-side analysts predict that NeuroPace will post -0.67 earnings per share for the current fiscal year.

About NeuroPace

NeuroPace, Inc is a medical technology company focused on developing therapies for people with drug-resistant epilepsy. The company’s principal product is the RNS System, an implantable responsive neurostimulation device designed to monitor brain activity, identify patterns associated with seizures, and deliver targeted electrical stimulation intended to reduce seizure frequency.

The RNS System includes an implanted neurostimulator, leads placed near seizure-producing areas of the brain, and external software and programming tools used by clinicians.